INTRODUCTION: Pancreatic acinar cell carcinoma (ACC) is a rare tumor with poorly defined prognosis. OBJECTIVE: Our objective was to compare a large population of patients with ACC to pancreatic ductal cell adenocarcinoma (DCC) in order to determine distinguishing characteristics and to assess survival. METHODS: Patients were identified from the National Cancer Database. Regression methods were used to identify differences between ACC and DCC and to identify predictors of survival for resected ACC. Eight hundred sixty-five patients with ACC were identified. RESULTS: Median tumor size was 6.9 cm (vs. 4.6 cm DCC); 32.1% had nodal metastases (vs. 48.0% DCC); and 47% had high-grade tumors (vs. 37.3% DCC). Resection margins were R0 77.3%, R1 13.7%, and R2 9.0%. Patients with ACC were more likely to be male, white, and have larger tumor size, no nodal involvement, or pancreatic tail tumors. Stage-specific 5-year survival was significantly better for resected ACC vs. DCC Stage I: 52.4% vs. 28.4%, II: 40.2% vs. 9.8%, III: 22.8% vs. 6.8%, and IV: 17.2% vs. 2.8%. On multivariable analysis, age < 65, well-differentiated tumors, and negative resection margins were independent prognostic factors for ACC. DISCUSSION: ACC carries a better prognosis than DCC. Aggressive surgical resection with negative margins is associated with long-term survival in these more favorable pancreatic cancers.
INTRODUCTION:Pancreatic acinar cell carcinoma (ACC) is a rare tumor with poorly defined prognosis. OBJECTIVE: Our objective was to compare a large population of patients with ACC to pancreatic ductal cell adenocarcinoma (DCC) in order to determine distinguishing characteristics and to assess survival. METHODS:Patients were identified from the National Cancer Database. Regression methods were used to identify differences between ACC and DCC and to identify predictors of survival for resected ACC. Eight hundred sixty-five patients with ACC were identified. RESULTS: Median tumor size was 6.9 cm (vs. 4.6 cm DCC); 32.1% had nodal metastases (vs. 48.0% DCC); and 47% had high-grade tumors (vs. 37.3% DCC). Resection margins were R0 77.3%, R1 13.7%, and R2 9.0%. Patients with ACC were more likely to be male, white, and have larger tumor size, no nodal involvement, or pancreatic tail tumors. Stage-specific 5-year survival was significantly better for resected ACC vs. DCC Stage I: 52.4% vs. 28.4%, II: 40.2% vs. 9.8%, III: 22.8% vs. 6.8%, and IV: 17.2% vs. 2.8%. On multivariable analysis, age < 65, well-differentiated tumors, and negative resection margins were independent prognostic factors for ACC. DISCUSSION: ACC carries a better prognosis than DCC. Aggressive surgical resection with negative margins is associated with long-term survival in these more favorable pancreatic cancers.
Authors: Kyle D Holen; David S Klimstra; Amanda Hummer; Mithat Gonen; Kevin Conlon; Murray Brennan; Leonard B Saltz Journal: J Clin Oncol Date: 2002-12-15 Impact factor: 44.544
Authors: Akhil K Seth; Pedram Argani; Kurtis A Campbell; John L Cameron; Timothy M Pawlik; Richard D Schulick; Michael A Choti; Christopher L Wolfgang Journal: J Gastrointest Surg Date: 2007-10-24 Impact factor: 3.452
Authors: Karl Y Bilimoria; David J Bentrem; Clifford Y Ko; Jamie Ritchey; Andrew K Stewart; David P Winchester; Mark S Talamonti Journal: Cancer Date: 2007-08-15 Impact factor: 6.860
Authors: Maeve A Lowery; David S Klimstra; Jinru Shia; Kenneth H Yu; Peter J Allen; Murray F Brennan; Eileen M O'Reilly Journal: Oncologist Date: 2011-10-31
Authors: Frank Bergmann; Sebastian Aulmann; Bence Sipos; Matthias Kloor; Anja von Heydebreck; Johannes Schweipert; Andreas Harjung; Philipp Mayer; Werner Hartwig; Gerhard Moldenhauer; David Capper; Gerhard Dyckhoff; Kolja Freier; Esther Herpel; Anja Schleider; Peter Schirmacher; Gunhild Mechtersheimer; Günter Klöppel; Hendrik Bläker Journal: Virchows Arch Date: 2014-10-09 Impact factor: 4.064
Authors: Courtney J Pokrzywa; Daniel E Abbott; Kristina A Matkowskyj; Sean M Ronnekleiv-Kelly; Emily R Winslow; Sharon M Weber; Alexander V Fisher Journal: J Gastrointest Surg Date: 2019-01-31 Impact factor: 3.452
Authors: Stephan Kruger; Michael Haas; Philipp Johannes Burger; Steffen Ormanns; Dominik Paul Modest; Christoph Benedikt Westphalen; Axel Kleespies; Martin Kurt Angele; Werner Hartwig; Christiane Josephine Bruns; Thomas Kirchner; Jens Werner; Volker Heinemann; Stefan Boeck Journal: J Cancer Res Clin Oncol Date: 2016-09-14 Impact factor: 4.553
Authors: Jesus M Matos; C Max Schmidt; Olivier Turrini; Narasimhan P Agaram; Marco Niedergethmann; Hans Detlev Saeger; Nipun Merchant; Cynthia S Johnson; Keith D Lillemoe; Robert Grützmann Journal: J Gastrointest Surg Date: 2009-06-03 Impact factor: 3.452